215 related articles for article (PubMed ID: 28659588)
21. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
Li H; Fang Y; Guo S; Yang Z
Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
[No Abstract] [Full Text] [Related]
22. Constitutive increase in active GLP-1 levels by the DPP4 inhibitor ASP4000 on a new meal tolerance test in Zucker fatty rats.
Tanaka-Amino K; Hatakeyama Y; Takakura S; Mutoh S
Pharmacol Res; 2009 Oct; 60(4):264-9. PubMed ID: 19520592
[TBL] [Abstract][Full Text] [Related]
23. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
[TBL] [Abstract][Full Text] [Related]
24. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jelsing J; Vrang N; van Witteloostuijn SB; Mark M; Klein T
J Endocrinol; 2012 Sep; 214(3):381-7. PubMed ID: 22761275
[TBL] [Abstract][Full Text] [Related]
25. Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119.
Zhang SY; Li J; Xie X
Acta Pharmacol Sin; 2014 Apr; 35(4):540-8. PubMed ID: 24681896
[TBL] [Abstract][Full Text] [Related]
26. YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model.
Park YH; Choi HH; Lee DH; Chung SY; Yang NY; Kim DH; Ju MK; Han TD; Nam SY; Kim KW
Arch Pharm Res; 2017 Jun; 40(6):772-782. PubMed ID: 28593550
[TBL] [Abstract][Full Text] [Related]
27. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
28. OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.
Ma SY; Ning MM; Zou QA; Feng Y; Ye YL; Shen JH; Leng Y
Acta Pharmacol Sin; 2016 Sep; 37(10):1359-1369. PubMed ID: 27264313
[TBL] [Abstract][Full Text] [Related]
29. Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119.
Arifin SA; Paternoster S; Carlessi R; Casari I; Ekberg JH; Maffucci T; Newsholme P; Rosenkilde MM; Falasca M
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):1132-1141. PubMed ID: 29883799
[TBL] [Abstract][Full Text] [Related]
30. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
Klemann C; Wagner L; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Mulvihill EE
Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
[TBL] [Abstract][Full Text] [Related]
32. Stimulating β-cell replication and improving islet graft function by AR231453, A GPR119 agonist.
Gao J; Tian L; Weng G; O'Brien TD; Luo J; Guo Z
Transplant Proc; 2011 Nov; 43(9):3217-20. PubMed ID: 22099761
[TBL] [Abstract][Full Text] [Related]
33. Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp.
Zhang Y; Chi J; Wang W; Hong J; Gu W; Wang B; Ning G
J Diabetes; 2015 Mar; 7(2):213-21. PubMed ID: 24889731
[TBL] [Abstract][Full Text] [Related]
34. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
35. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.
Chu ZL; Carroll C; Chen R; Alfonso J; Gutierrez V; He H; Lucman A; Xing C; Sebring K; Zhou J; Wagner B; Unett D; Jones RM; Behan DP; Leonard J
Mol Endocrinol; 2010 Jan; 24(1):161-70. PubMed ID: 19901198
[TBL] [Abstract][Full Text] [Related]
36. Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Hikida K; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Minami M; Shiotani M
J Pharmacol Sci; 2016 Dec; 132(4):255-261. PubMed ID: 27889414
[TBL] [Abstract][Full Text] [Related]
37. Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model.
Sueyoshi R; Woods Ignatoski KM; Okawada M; Hartmann B; Holst J; Teitelbaum DH
Am J Physiol Gastrointest Liver Physiol; 2014 Aug; 307(4):G410-9. PubMed ID: 24970775
[TBL] [Abstract][Full Text] [Related]
38. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
[TBL] [Abstract][Full Text] [Related]
39. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice.
Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
Biol Chem; 2014 Apr; 395(4):453-64. PubMed ID: 24323890
[TBL] [Abstract][Full Text] [Related]
40. Dipeptidyl Peptidase-4 Regulates Hematopoietic Stem Cell Activation in Response to Chronic Stress.
Zhu E; Hu L; Wu H; Piao L; Zhao G; Inoue A; Kim W; Yu C; Xu W; Bando YK; Li X; Lei Y; Hao CN; Takeshita K; Kim WS; Okumura K; Murohara T; Kuzuya M; Cheng XW
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
